Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chih-Jen, Wei, Yu-Jui, Chang, Hsu-Liang, Chang, Pi-Yu, Tsai, Chung-Chen, Chen, Yen-Hsu, Hsueh, Po-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534785/
https://www.ncbi.nlm.nih.gov/pubmed/33060041
http://dx.doi.org/10.1016/j.jmii.2020.09.002
_version_ 1783590363555954688
author Yang, Chih-Jen
Wei, Yu-Jui
Chang, Hsu-Liang
Chang, Pi-Yu
Tsai, Chung-Chen
Chen, Yen-Hsu
Hsueh, Po-Ren
author_facet Yang, Chih-Jen
Wei, Yu-Jui
Chang, Hsu-Liang
Chang, Pi-Yu
Tsai, Chung-Chen
Chen, Yen-Hsu
Hsueh, Po-Ren
author_sort Yang, Chih-Jen
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).
format Online
Article
Text
id pubmed-7534785
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
record_format MEDLINE/PubMed
spelling pubmed-75347852020-10-06 Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review Yang, Chih-Jen Wei, Yu-Jui Chang, Hsu-Liang Chang, Pi-Yu Tsai, Chung-Chen Chen, Yen-Hsu Hsueh, Po-Ren J Microbiol Immunol Infect Review Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2021-02 2020-10-05 /pmc/articles/PMC7534785/ /pubmed/33060041 http://dx.doi.org/10.1016/j.jmii.2020.09.002 Text en © 2020 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Yang, Chih-Jen
Wei, Yu-Jui
Chang, Hsu-Liang
Chang, Pi-Yu
Tsai, Chung-Chen
Chen, Yen-Hsu
Hsueh, Po-Ren
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
title Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
title_full Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
title_fullStr Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
title_full_unstemmed Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
title_short Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
title_sort remdesivir use in the coronavirus disease 2019 pandemic: a mini-review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534785/
https://www.ncbi.nlm.nih.gov/pubmed/33060041
http://dx.doi.org/10.1016/j.jmii.2020.09.002
work_keys_str_mv AT yangchihjen remdesiviruseinthecoronavirusdisease2019pandemicaminireview
AT weiyujui remdesiviruseinthecoronavirusdisease2019pandemicaminireview
AT changhsuliang remdesiviruseinthecoronavirusdisease2019pandemicaminireview
AT changpiyu remdesiviruseinthecoronavirusdisease2019pandemicaminireview
AT tsaichungchen remdesiviruseinthecoronavirusdisease2019pandemicaminireview
AT chenyenhsu remdesiviruseinthecoronavirusdisease2019pandemicaminireview
AT hsuehporen remdesiviruseinthecoronavirusdisease2019pandemicaminireview

Ejemplares similares